Markets
Stock market valuation metrics
Careful there (Anadolu/Getty Images)

By any historic metric, this market is getting closer to the edge

The evidence is piling up.

It’s been a great run, the best two-year romp for the S&P 500 since the late 1990s, with a bit of a Santa Claus rally perhaps still to come.

But allow me to be the proverbial fly in the eggnog and note the fact that several of the market’s most time-tested valuation metrics appear to be flashing a giant, red warning signal, complete with sirens.

I know, I know. Valuation is a bit of a quaint concept for today’s investors, who are enjoying gobsmacking gains from electronic crypto doodads and newly minted AI-related behemoths.

But traditionally, the market’s ability to keep climbing is contingent on the earnings that companies are able to generate, the expansion of the economy, and the relative risks and rewards of letting your money ride in the stock market or enjoying safe and steady fixed income on the sidelines. On all those counts, the level of prices on stocks is stretching the limits of traditional stock-market logic.

Earnings

As I’ve said before, the standard forward price-to-earnings multiple of the S&P 500 right now suggests investors are paying a historically high premium for exposure to the market.

But other longer-term iterations of price-to-earnings metrics, like Yale University finance professor Robert Shiller’s Cyclically Adjusted Price-to-Earnings Ratio (CAPE), clearly shows the market is at some of its most expensive levels in history.

For instance, stocks are far more expensive — in terms of their actual earnings over the last decade — than during the bull market of the 1920s, which ended cataclysmically in 1929. The only time on record when they were pricier was during the dot-com boom of the late 1990s, which had a kind of disappointing finale as well.

The economy

Another way to look at the markets is their capitalization as a percentage of the total economy. This yardstick is sometimes known as the Buffett Indicator because of the fact that its one of Warren Buffett’s favorites. It has been going nuts recently, rising into never-before-seen territory, with total capitalization of the stock market — roughly $55 trillion — approximately double the size of the US GDP. (Of course, US companies, especially the multinational megacap tech giants, have seen foreign sales swell as a share of total revenues, so the utility of having the US economy as the denominator has diminished over time.)

In a 2001 piece in Fortune, the Oracle of Omaha said, “If the percentage relationship falls to the 70% or 80% area, buying stocks is likely to work very well for you. If the ratio approaches 200% — as it did in 1999 and a part of 2000 — you are playing with fire.”

No wonder Buffett has been building cash.

Risk-reward trade-offs

All the above warnings signals are derived from the stock market in isolation. But the whole idea of building a portfolio is to weigh your options across asset classes. That’s why looking at the “equity-risk premium” can be helpful.

This chart basically gives you an estimate of how much the market is compensating shareholders for putting their money at risk on the equity-market rollercoaster versus the virtually guaranteed rewards of sticking your cash in government bonds. (Yields there are still high, by the way, with three-month Treasury bills paying almost 4.50%.)

As you can see, you’re getting what’s known on Wall Street by the technical term of bupkis.

So what?

Of course, valuation metrics are famously terrible tools for timing the market. Just because the stocks appear insanely overvalued at the moment, it doesn’t follow that the market is in danger of an imminent collapse.

There are even some reasons why these metrics might be less helpful than they’ve been in the past. For instance, we’ve never had companies in the stock market as big as they currently are in terms of market capitalization. (Apple, Nvidia, and Microsoft are all worth more than $3 trillion.)

That might just reflect the fact that those companies are more powerful players in the economy and thus it makes sense that market capitalization to GDP would be higher than it has been historically.

Likewise, the incoming Trump administration is widely expected to loosen regulatory rules and cut taxes, meaning that the market could be pricing in higher profits than usual going forward. Sure, maybe. But if the market does take a header, or even merely stalls out for a while, don’t be too surprised.

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets
Luke Kawa

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.